Selection of what blood glucose monitoring system to utilize has become an issue for physicians, diabetes educators, pharmacists, and patients. The field of competing makes and models of blood glucose monitoring systems has become crowded, with manufacturers touting improvements in accuracy, ease of use/alternate site options, stored results capacity, software evaluation tools, and/or price point.
Introduction
Sel f-monitoring of blood glucose has long been established as a critical tool in maintaining adequate glycemic control, as well as lowering glycosylated hemoglobin (HbA 1c ) in patients with diabetes. [1] [2] [3] [4] Selection of which blood glucose monitoring system to utilize has become an issue for physicians, diabetes educators, pharmacists, and patients. The field of competing makes and models of blood glucose monitoring systems has become crowded with manufacturers touting improvements in accuracy, ease of use/alternate site options, stored results capacity, software evaluation tools, and/or price point. Accuracy and reliability of at least two current models appear to be similar 5 and all new devices are tremendous improvements on the early "time dependent, wipe strip and insert for test devices" that served as "gold standards" for today's systems. Determining which make and model best serve an individual's needs is often to be assumed to be the responsibility of the primary care provider, but current market conditions in the United States (U.S.) seem to dictate otherwise in the general population. This study attempts to determine what devices are most recommended by pharmacist educators and factors that influence such decisions, comparing recommendations to actual sales of monitors and strips to assess the impact (if any) of pharmacist recommendations on patient's choice of monitoring system.
Methods
Personal interviews were conducted with 12 pharmacists practicing in the Midwest region of the U.S. representing over 50 community pharmacy locations, as well as academic pharmacist educators providing clinical pharmacy services to indigent and institutional patient populations. Additional information about pharmacist monitor system and test strip recommendations was found in Pharmacy Times OTC Products 2006 Survey of Pharmacist Recommendations. 6 National sales data were provided by a major pharmacy wholesaler for the previous 12 months as a comparison of actual sales versus recommendation preferences reported by pharmacists.
Results
Academic and community pharmacists surveyed agreed on factors considered when making product recommendations to patients. Reputation of manufacturer for accuracy, monitor reliability, sample size required, alternate testing site capability, memory available, time and date stamp, optional software for downloading results, and ease of use/display font size were all considered important factors for helping determine what monitoring system fit an individual patient's needs the best. Physicians often write prescriptions for "monitor covered by insurance plan" to try and avoid multiple phone calls from the pharmacy about what is covered under the patient's benefit plan. In those cases the pharmacist must determine the plan's formulary product preference, if any, and notify the physician's office of make and model of device provided to the patient. By comparing the percentage of pharmacist recommendations of specific products to the percentage of total category sales of specific product models, an estimation of how often the patient followed the pharmacist's suggestion can be made. Differences in suggested models versus actual sales of monitor kits can vary due to individual preference, coupons provided/free monitor give-away programs, and what formulary restrictions were in place at the time of inquiry. The top three recommended monitors had varying degrees of actual patient selection. (Table 1 ). Accu-Chek ® monitors were recommended 34.65% of the time and represented 28.58% of sales, with a success rate of 82.48% of being the monitor selected. OneTouch ® monitors had fewer pharmacist recommendations (27.72% of total) but represented 31.43% of sales, indicating possible patient brand loyalty or formulary preference for that product. FreeStyle ® monitors came in third for pharmacist recommendations and were selected by the patient 61.68% of the time. The "other monitor" category included several independent monitoring systems often sold under private labeling. Those systems were selected 60.89% of the time by patients given that suggestion. Included in the "other monitor" category was the new disposable monitor marketed as the Sidekick ® . Based on sales data provided, the Sidekick ® made up 2.87% of "other monitor" category sales, representing 68% of the "other monitor" segment. The SideKick ® is the only totally disposable system available in the U.S. market. Each monitor comes with 50 testing strips and can be purchased for less than the equivalent number of major brand test strips. While inexpensive and having some use for emergency or occasional use, pharmacists interviewed expressed concern about possible variables in each disposable device's electronic circuitry, resulting in a potential for variance, particularly in patients attempting tight glucose control. Test strip recommendations and sales closely paralleled monitor system recommendations and sales with the exception of the Ascencia (Glucometer) Elite ® ( Table 2 ). This monitoring system is in the process of being phased out by the manufacturer, but existing systems are still in need of strip supplies. 
Conclusions
While patients frequently follow pharmacist monitoring system suggestions, the ultimate deciding factor is most often the final out-of-pocket cost to the patient. Almost all monitoring systems are available for little to no cost to the individual via monitor give-away programs and coupons, but testing strip and lancet supplies vary greatly in final price based on the individual's prescription benefit plan formulary. As a result, cost of supplies becomes the most important determining factor in final monitor selection at the patient level. If the patient cannot afford to perform the recommended daily testing intervals, all other determining factors become moot. Getting consistent test results from a reliable, affordable monitor, training patients on what their test results mean, and then taking appropriate clinical action based on those results were priorities for all providers interviewed. Without the right test information collected at the right time and adequate education of the patient on what their results imply, no monitoring system can be successful in helping reduce glycemic excursions from desired levels.
